OmniAb (OABI) Expected to Announce Quarterly Earnings on Tuesday

OmniAb (NASDAQ:OABI) is expected to announce its earnings results after the market closes on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $10.13 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

OmniAb Trading Down 4.4 %

NASDAQ:OABI opened at $3.25 on Tuesday. The firm has a 50-day moving average price of $3.45 and a two-hundred day moving average price of $3.84. OmniAb has a twelve month low of $3.10 and a twelve month high of $5.72. The company has a market capitalization of $458.95 million, a P/E ratio of -5.24 and a beta of -0.14.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OABI. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark restated a “buy” rating and issued a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

Insider Activity at OmniAb

In other OmniAb news, CEO Matthew W. Foehr sold 41,811 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the sale, the chief executive officer now owns 3,749,639 shares in the company, valued at $12,148,830.36. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kurt A. Gustafson sold 15,526 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $50,304.24. Following the sale, the chief financial officer now owns 212,720 shares of the company’s stock, valued at approximately $689,212.80. The trade was a 6.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock valued at $376,601 over the last ninety days. Corporate insiders own 8.60% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.